Prostate Cancer Therapeutics Market Size & Share 2025 – 2034

Prostate Cancer Therapeutics Market Size

The global prostate cancer therapeutics market was valued at USD 12.6 billion in 2024. The market is expected to reach from USD 13.5 billion in 2025 to USD 29.9 billion in 2034, growing at a CAGR of 9.2% during the forecast period.

This high market growth is driven by the increasing prevalence of prostate cancer worldwide, rising awareness about cancer among general population, increasing government initiatives towards early-stage cancer detection, increased availability of technologically advanced diagnostic modalities, increased advancements in treatment methods, and expanding pipeline of novel therapies.
 

Prostate cancer is one of the most common tumors diagnosed in men all over the world. There is an increasing prevalence of prostate cancer due to an aging population and lifestyle changes such as diet, smoking, and level of physical activities. For instance, new cases of prostate cancer in the U.S. was estimated to reach 299,010 by 2024. [Source: National Institutes of Health (NIH)]. As the number of confirmed cases rises, so does the need for effective treatment choices to meet that need.
 

Moreover, awareness about the risks, symptoms, and the need for timely diagnosis of prostate cancer through educational campaigns and government-sponsored screening programs is gaining traction. For example, in August 2023, George Washington University (GW) Cancer Center initiated a campaign for prostate cancer awareness. This social media kit helps cancer control organizations develop evidence-based strategies for prostate cancer detection. This increased awareness leads to higher screening and diagnosis of prostate cancer, increasing the need for prostate cancer therapeutics.
 

Prostate cancer therapeutics includes treatments and methods used to manage and treat prostate cancer, a malignant transformation that occurs in the prostate gland of males. Prostate cancer therapeutics are focused on controlling the metastasizing cells, along with relieving symptoms, enhancing quality of life, and prolonging survival when a patient is diagnosed with prostate cancer.
 

Prostate Cancer Therapeutics Market Trends

The prostate cancer therapeutics industry is witnessing significant developments that shape its growth trajectory. Factors such as, innovations in therapies, a shift towards personalized medicine, growing adoption of integrated artificial intelligence in healthcare and machine learning, as well as increased focus on minimally invasive treatments.
 

• The healthcare approach now emphasizes patient participation in care processes, fostering collaboration between patients and healthcare providers from the initial stages. The patient experience, quality of life considerations, and clinical objectives have become essential factors in treatment decisions and medication selection.
   
• High-Intensity Focused Ultrasound (HIFU) and focal therapy emerge as less invasive alternatives to radical prostatectomy, offering shorter recovery periods, reduced complications, and improved quality of life for localized prostate cancer patients. EDAP TMS reported a 34.8% increase in HIFU treatment sales in 2023 compared to 2022.
   
• The approval of Profound Medical's TULSA-PRO system in 2023 expanded minimally invasive treatment options in the U.S. According to the American Cancer Society's 2024 report, 300,000 men underwent minimally invasive procedures in 2023, representing a 25% increase from 2021.
   
• Combined therapy approaches, such as surgery with radiotherapy or chemotherapy with immunotherapy, demonstrate superior outcomes. The National Cancer Institute's 2023 report indicates that combination therapies show 35% higher effectiveness compared to single treatment methods.
   
• In March 2023, Merck received FDA approval for KEYTRUDA combined with chemotherapy for metastatic prostate cancer, demonstrating a 27% reduction in disease progression. AstraZeneca and Daiichi Sankyo's ENHERTU combination received breakthrough designation for hormone-resistant prostate cancer treatment in January 2024, further strengthening market development.
   

Prostate Cancer Therapeutics Market Analysis

Based on therapy, the prostate cancer therapeutics market is classified into hormonal therapy, chemotherapy, immunotherapy, targeted therapy, and other therapies. The hormonal therapy segment dominated the market in 2024 and was valued at USD 8.7 billion growing from USD 7 billion in 2021.
 

• Hormonal therapy, specifically Orgovyx (relugolix), achieved a 96.7% reduction in testosterone levels during clinical trials, demonstrating its effectiveness in treating prostate cancer. This drug received FDA approval in 2021. According to the American Cancer Society's 2023 report, more than 288,300 new cases were diagnosed, making hormonal therapy a key treatment option. The therapy's ability to lower androgen hormone levels helps control cancer progression, reduce symptoms, and improve patient survival rates.
   
• In addition, the American Association of Urology reported a 30% increase in the prescribing rates of new hormonal drugs for the treatment of advanced prostate cancer in Europe after the 2022 guideline update. This increase reflects the direct influence of updated treatment protocols on regional healthcare practices.
   
• Further, the expansion of hormonal therapy options now includes next-generation anti-androgens (enzalutamide and apalutamide) and novel treatments like abiraterone acetate. These medications offer enhanced treatment efficacy, improved targeting capabilities, and fewer side effects compared to conventional methods, contributing to market expansion.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on drug class, the prostate cancer therapeutics market is classified into androgen receptor inhibitors, GnRH receptor antagonists, PARP inhibitors, immune checkpoint inhibitors, and other drug classes. The androgen receptor inhibitors segment dominated the market in 2024 with a market share of 35.5%.
 

• Prostate cancer is one of the most common cancers detected worldwide. For instance, the American Cancer Society stated that about 299,010 new cases of prostate cancer were diagnosed in the Americas in 2023, indicating a 9% increase from 2022. The dependency of prostate cancer on androgens has made the disease closely related to androgen receptor inhibitors (ARIs) becoming major treatment options.
   
• The key therapies are Enzalutamide (Xtandi), Apalutamide (Erleada), and Darolutamide (Nubeqa) approved by FDA for metastatic hormone sensitive prostate cancer in August 2022.
   
• ARIs are also used in the treatment of castration-resistant prostate cancer where the disease is no longer responsive to Androgen Deprivation Therapy (ADT). Such agents are able to manage Castration-Resistant Prostate Cancer (CRPC) by targeting Androgen Receptor (AR) signaling pathways and overcoming many resistance mechanisms developed over time.
   
• In addition, treatment with these drugs provides a higher quality of life with less severe side effects, making them more well tolerated than standard chemotherapy. This enhances patient compliance and adherence to treatment regimens, especially for those who require long-term therapy.
   

Based on route of administration, the prostate cancer therapeutics market is classified into oral and injectable. The oral segment dominated the market and is expected to grow at a pace of 9% CAGR between 2025 – 2034.
 

• Compared to injections, oral medications are easier to manage and more convenient to consume for patients. Patients can follow their treatment plans more easily as fewer clinic visits are required. The improvement in ease of use enhances patient satisfaction and improves their quality of life during cancer treatment, especially during inflammation.
   
• Moreover, pharmaceutical companies also continue to invest in the development of oral medicines for prostate cancer which has led to the discovery of new molecular targets and therapeutic agents. In 2023, Pfizer’s research and development  spending reached USD 13.8 billion and Merck’s research spending was USD 13.5 billion.
   
• AstraZeneca also increased its research and development spending for 2023 by 10% to USD 9.5 billion, with every dollar going toward cancer research. These developments will increase the number of treatment options available and improve their effectiveness while reducing side effects and better managing the progression of the disease.
   

Based on distribution channel, the prostate cancer therapeutics market is segmented into hospital pharmacy, brick and mortar, and e-commerce. The hospital pharmacy segment dominated the market in 2024 and is anticipated to reach USD 19 billion by the end of forecast period.
 

• To manage complex therapies, including those used in the treatment of prostate cancer, hospital pharmacies offer specialized care and expertise. Pharmacists and pharmacy staff are trained to manage and handle oncology medications, drug therapy, monitor adverse effects, and drug interactions.
   
• Moreover, these pharmacies have access to a wide spectrum of advanced specialized therapies which include chemotherapy agents, hormonal therapies, immunotherapies, and targeted therapies provided for patients suffering from prostate cancer. These pharmacies ensure timely supply of marketed medications, including those under clinical trial for prostate cancer patients.
   

In 2024, the North America region accounted for the largest share of 39.2% in the prostate cancer therapeutics market. The U.S. market was valued at USD 3.7 billion in 2021. The country dominated the North American market in 2023 with USD 4.3 billion growing from USD 4 billion in 2022.
 

• North America has well-equipped hospitals, cancer specialty hospitals, and comprehensive oncology care facilities that help in early diagnosis and treatment of prostate cancer. Hence America is one of the leading countries in the world for market growth.
   
• The region is a leader in healthcare spending, and public and private organizations are working together to develop new therapies for prostate and other forms of cancer, which makes innovation economically possible. This helps in creating and introducing new drugs that can be used on a larger scale.
   
• For example, the Centers for Medicare and Medicaid Services (CMS.gov) reported that U.S. healthcare spending in 2023 was USD 4.7 trillion, which is 18% of its economy. The combined government and private spending is expected to increase to USD 7.2 trillion by 2031, with an average yearly increase of 5.5%.
   

In Europe region, Germany prostate cancer therapeutics market is projected to grow remarkably in the coming years.
 

• Germany is a central hub for clinical research and development in oncology, especially in the southeastern region of Europe. The integration of academic institutions and pharmaceutical and research companies conducts clinical trials related to new drugs, cancer biomarkers, and other types of therapies. In 2023, Germany had over 2,300 oncology clinical trials, 15% of which were for prostate cancer.
   
• Germany is, and has been, a central hub for clinical research and development in oncology, especially in the southeastern region of Europe. The integration of academic institutions and pharmaceutical and research companies conducts clinical trials related to new drugs, cancer biomarkers, and other types of therapies. In 2023, Germany had over 2,300 oncology clinical trials, 15% of which were for prostate cancer.
   
• In 2023, the German Federal Ministry of Education and Research budgeted USD 2.9 billion for medical research, out of which USD 681.5 million were allocated cancer research. The German Cancer Research Center DKFZ funded 45 new clinical trials for prostate cancer, which marked a 25% growth from 2021.
   
• Further, these innovations in cancer therapeutics, Germany is moving toward patient-centered treatment regimens where individual treatment methods, physician-patient decision making, and patient empowerment are top priorities. Oncologists and healthcare practitioners work toward best-possible outcomes together with the patients who are concerned about their quality of life and treatment adherence.
   

Japan holds a dominant position in the Asia Pacific prostate cancer therapeutics market.
 

• Japan's elderly population, especially men, are at higher risk of getting prostate cancer. The National Cancer Center Japan reported that there were 92,000 new cases of prostate cancer in 2021, and this number is expected to rise to 98,000 by 2024.
   
• The Japanese government's 2023 healthcare budget set aside USD 290.7 million for cancer treatment, which includes therapy for prostate cancer. In March 2023, Astellas Pharma increased its production capacity for prostate cancer medication at their Yaizu facility to meet the rising demand within the country.
   
• Also, the current laws in the country ensure proper review and approval of new prostate cancer treatments. The introduction and use of new treatment methods that are breakthrough therapies and innovative ways of treatment are fast-tracked to the market to help patients and healthcare providers.
   

Prostate Cancer Therapeutics Market Share

The market shows strong competition, especially with the ongoing development of hormone therapies, targeted therapies, chemotherapy, and immunotherapy. Top players such as AstraZeneca Plc, Bayer AG, Johnson & Johnson, Pfizer Inc., and Sanofi S.A. hold about 45% of the total market share through their strong portfolios of androgen receptor inhibitors (ARIs), PARP inhibitors, and chemotherapy drugs.
 

These companies are working to expand their indications, get regulatory approvals, and increase their research and development  spending to develop new treatments with better effectiveness and safety. The use of oral and combination therapies is growing, which improves competition and patient outcomes. Additionally, the competitive environment is expanding as new biotech companies and smaller pharmaceutical companies enter the market with new immunotherapies and precision medicine.
 

Prostate Cancer Therapeutics Market Companies

Prominent players operating in the prostate cancer therapeutics industry include:

• Astellas Pharma
• AstraZeneca
• Bayer
• Dendreon Pharmaceuticals
• Exelixis
• Ferring
• GlaxoSmithKline
• Ipsen Pharma
• Johnson & Johnson
• Novartis
• Pfizer
• Sanofi
• Sumitomo Pharma America
• Takeda Pharmaceutical
• Tolmar
   
• Johnson & Johnson (Janssen Pharmaceuticals) is singularly focused on androgen receptor inhibition and advanced hormone therapy with Zytiga and Erleada, their leading prostate cancer treatments. These therapies improve patient outcomes.
   
• Pfizer Inc. collaborates in the co-development of the next generation androgen receptor inhibitor, Xtandi (enzalutamide), while simultaneously directing significant funding towards novel oncology research aimed at improving survival with advanced prostate cancer.
   

Prostate Cancer Therapeutics Industry News

• In April 2024, Astellas Pharma Inc. has received approval from the European Commission to expand the label for XTANDI (enzalutamide). This approval allows XTANDI to be used either alone or in combination with androgen deprivation therapy (ADT) for treating adult men diagnosed with high-risk biochemical recurrent (BCR), non-metastatic hormone-sensitive prostate cancer (nmHSPC) who are not suitable candidates for salvage radiotherapy. This extension broadens the treatment options available to this specific patient population, offering a new therapeutic approach to manage their condition effectively.
   
• In February 2023, Pfizer has reported positive findings from the Phase 3 TALAPRO-2 trial of TALZENNA (talazoparib), an oral PARP inhibitor, in combination with XTANDI (enzalutamide). These results highlight the potential of combining TALZENNA with XTANDI as a promising treatment option for patients with mCRPC, addressing an unmet medical need in advanced prostate cancer therapy.
   

The prostate cancer therapeutics market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Therapy

• Hormonal therapy
• Chemotherapy
• Immunotherapy
• Targeted therapy
• Other therapies

Market, By Drug Class

• Androgen receptor inhibitors
• GnRH receptor antagonists
• PARP inhibitors
• Immune checkpoint inhibitors
• Other drug classes

Market, By Route of Administration

• Oral
• Injectable

Market, By Distribution Channel

• Hospital pharmacy
• Brick and mortar
• E-commerce

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE